Ermenegildo Zegna NV
ZGN
YETI Holdings
YETI
DOMINOS PIZZA ENTERPRISES LIMITED UNSP ADR EACH REPR 0.5 ORD SHS
DMZPY
4
Cars.com
CARS
5
LIFE HEALTHCARE GROUP HOLDINGS UNSPON ADR EA REPR 4 ORD ZAR0.00
LTGHY
US Stock MarketDetailed Quotes
DERM Journey Medical
- 7.190
- +0.600+9.10%
Close Apr 4 16:00 ET
- 7.161
- -0.030-0.41%
Post 20:01 ET
166.12MMarket Cap-9.99P/E (TTM)
7.290High6.140Low355.01KVolume6.450Open6.590Pre Close2.48MTurnover3.18%Turnover RatioLossP/E (Static)23.10MShares7.29052wk High8.27P/B80.37MFloat Cap3.20052wk Low--Dividend TTM11.18MShs Float10.200Historical High--Div YieldTTM17.45%Amplitude1.020Historical Low6.992Avg Price1Lot Size
Market Insights
Discussing
Chinese stock earnings surge: Will profit sustain the rally?
1. Which sectors are likely to be market highlights this season? 2. With the government's emphasis on technological innovation and sustaina
Moomoo News Global
Mar 4 23:26
China's Two Sessions: Key Takeaways on Stock Price Movements Before and After the Meetings
Journey Medical Stock Forum
Breakthrough: First Low-Dose Minocycline Treatment for Rosacea Shows Superior Results
1 min ago
Journey Medical Corporation Launches Emrosi™ (40 Mg Minocycline Hydrochloride Modified-Release Capsules, 10 Mg Immediate Release and 30 Mg Extended Release) for the Treatment of Rosacea
Journey Medical Corporation Launches Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea
Monday, 24th March at 8:30 am
Initial distribution of Emrosi to pharmacies ongoing
First prescriptions of Emrosi filled
SCOTTSDALE, Ariz., March 24, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) ("Journey Medical"), a commercial-st...
Journey Medical Corporation Announces Publication in the Journal of the American Medical Association - Dermatology of the Phase 3 Clinical Trial Results of Emrosi™ (DFD-29) to Treat Rosacea
Wednesday, 5th March at 4:01 pm
DFD-29 (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) achieved the co-primary and all secondary endpoints with no significant safety issues when administe...
Journey Medical Corporation to Host Conference Call to Discuss U.S. Commercial Launch Plan for Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea
Thursday, 23rd January at 8:30 am
SCOTTSDALE, Ariz., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) ("Journey Medical"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ...
3 mins ago
Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 Mg) for the Treatment of Rosacea
Benzinga· 3 mins ago
Poster Presented on Dermal and Systemic Pharmacokinetics of Oral DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) versus Oral Doxycycline 40 mg Capsules (Oracea) in Healthy Subjects
With its modified-release formulation, DFD-29 (40 mg) provides higher dermal concentration than doxycycline from Day 1 onward at a similar dose, expected to transl...
PDUFA scheduled for early November. If approved, annual market potential exceeding 100 million USD.
No comment yet